Jingyin Pharma Licenses Long-Acting Factor XI siRNA Therapy; Subcutaneous Efgartigimod Shows Strong CIDP Efficacy in China Subgroup

Amino Observation - Original Production by the Innovative Drug Team

Author | Huang Kai

/ 01 /

Market Express

1) Sirius Therapeutics' Long-Acting Factor XI Small Interfering RNA Therapy Out-Licensed

On May 20, Sirius Therapeutics announced that it had entered into a strategic partnership with CRISPR Therapeutics to jointly develop and commercialize SRSD107, a next-generation long-acting Factor XI (FXI) targeted small interfering RNA (siRNA) therapy, for the treatment of thrombotic and thromboembolic diseases.

Over $6 billion! 3SBIOINC Licenses PD-1/VEGF Bispecific Antibody to Pfizer

On May 20, 3SBIOINC announced that the company, along with its subsidiaries 3SBio Group and 3SBio Genetech, signed an agreement with Pfizer granting Pfizer exclusive rights to develop, manufacture, and commercialize the breakthrough PD-1/VEGF bispecific antibody SSGJ-707 globally (excluding mainland China). According to the agreement, 3SBIOINC will receive a non-refundable and non-creditable upfront payment of $1.25 billion, as well as potential development, regulatory approval, and sales milestone payments of up to $4.8 billion. The company will also receive tiered royalties in the double-digit percentage range based on product sales in the licensed territories. Additionally, Pfizer will subscribe to $100 million worth of ordinary shares of 3SBIOINC on the effective date of the agreement.

/ 02 /

Capital Information

1) CureGene Completes Over RMB 100 Million in Series B+ Financing

On May 20, CureGene Pharmaceutical Co., Ltd. announced the completion of its oversubscribed Series B+ financing round totaling over RMB 100 million. The proceeds will primarily be used to advance the Phase III clinical development of its core cardiovascular and cerebrovascular product, CG-0255.

/ 03 /

Pharmaceutical News

1) Subgroup Data from China in the ADHERE Study of Efgartigimod Subcutaneous Injection for CIDP Treatment Released

On May 19, at the annual meeting of the Peripheral Nerve Society (PNS) held in Edinburgh, UK, the China subgroup data from the ADHERE study was presented in poster format. The study results showed that subcutaneous efgartigimod injection demonstrated clinically meaningful efficacy in Chinese patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The response rate for Chinese enrolled patients in Phase A was 77.6%, compared to 66% for the global subgroup.

2) The first subject has been dosed in the Phase III bridging clinical trial of the new oral SERD drug Elacestrant in China.

On May 20, Jin Sai Pharmaceuticals announced significant progress in the Phase III bridging clinical trial conducted in China for elacestrant (Alasotam), the world’s first oral selective estrogen receptor degrader (SERD) drug — Professor Shao Zhimin's team from Fudan University Shanghai Cancer Center successfully completed the first patient dosing in the study.

/ 04 /

Digital Healthcare Daily

1) Zhang Xiaodong, Founder and CEO of Magna Health: Future Focus on Three Directions

On May 20, at the ecological cooperation conference held by Maxure Health, the company's founder and CEO Xiaodong Zhang stated that in the future, Maxure Health will focus on three directions: "broader coverage of commercial health insurance, new infrastructure for diversified payment of innovative drugs and medical devices, and the pharmaceutical payment ecosystem."

PS: Welcome to scan the QR code below to add the WeChat ID of AminoGenius for communication.